When
-
- Summarize evidence from pivotal clinical trials and practice guidelines on BTK inhibitor efficacy, safety, and mechanistic/selectivity differences, including as single-agent approaches or as part of novel combinations
- Recommend personalized BTK inhibitor therapy for patients with treatment-naïve CLL based on prognostic information, the presence of comorbidities, and safety considerations
- Select individualized, sequential BTK inhibitor options for the management of patients with relapsed/refractory CLL or for individuals who develop therapeutic intolerance
- Manage adverse events associated with the use of novel targeted approaches with BTK inhibitors in the CLL setting